Affordable Ozempic: Another ‘Fair & Lovely Moment’ For India’s Arranged Marriage Market – OpEd |
There are moments in the journey of each society when a product enters the bloodstream of culture and changes the rules of desirability through aspirations. Fair & Lovely did it with skin tone in India. Less costlier versions of Ozempic may do it with body weight.
India’s arranged marriage market has always been brutally efficient in ranking human worth. Height, skin colour, caste, salary, family background – everything is indexed, filtered and negotiated. And somewhere in that spreadsheet of expectations, ‘slim’ has remained a constant, especially for women. Until now, weight was at least partially insulated by the language of health, genetics, or ‘after marriage it will improve’. It was a soft disqualification, not always a permanent one.
Ozempic, and drugs like it, threaten to harden that softness into something far more unforgiving. Because for the first time, weight loss is being reframed as a purchasable outcome. This is what makes the shift dangerous in a country where millions of biodatas already list “fair” and “homely”, the arrival of a pharmaceutical shortcut transforms “slim” from a preference into an expectation. The logic becomes insidious in its simplicity: if weight loss is accessible, then being overweight is no longer a circumstance but it is a choice. And in a market that penalises deviation, choice becomes culpability.
You can already see the early signs. Stories of individuals using semaglutide-based drugs before re-entering the marriage market are beginning to circulate. They are not medical choices, but social upgrades. Weight loss is no longer about health markers. It is becoming a marker of eligibility – moving from the “maybe” pile to the “yes” pile.
The arranged marriage ecosystem thrives on signalling. A degree signals intellect. A salary signals stability. Fair skin signals beauty (however problematic that metric is). Ozempic introduces a new signal: discipline through consumption. The ability to afford and access weight-loss medication becomes, in itself, a marker of class. And like all such markers, it will cascade with cheaper drug availability.
Families will begin to ask questions – not just “what is her weight?” but “has she tried something?” Matrimonial profiles may not explicitly state it, but expectations will adjust. Prospective brides, and increasingly grooms, will face a subtle but sharp recalibration: if others are using these tools, why aren’t you? This is where the brutality deepens. Because unlike fairness creams, which promised transformation but delivered illusion, Ozempic works. The results are visible and undeniable. That makes the pressure far more intense. When transformation becomes real, the refusal to transform becomes socially legible. And that has consequences.
First, it medicalises desirability. What was once a social preference now enters the domain of prescription. Doctors, willingly or otherwise, become gatekeepers to marriage eligibility. Off-label usage (already common) will expand. The line between treating diabetes and treating societal expectations will blur.
Second, it amplifies inequality. Even the access to the less costlier drugs is uneven. The urban upper-middle class will adopt them faster, setting new baselines of appearance. The rest will be measured against those baselines without having the same tools. The arranged marriage market, already stratified, will acquire another layer of exclusion.
Third, it intensifies gendered pressure. While men will face some of this shift, women will bear the brunt. They always do in markets of appearance. The expectation to be ‘marriage-ready’ has historically meant conforming to narrow standards of beauty. Ozempic tightens those standards further, wrapping them in the language of modern medicine.
And then there is the psychological cost. Rejection in the arranged marriage system is rarely personal. Add to that the knowledge that one could, theoretically, ‘fix’ a disqualifying trait through medication, and rejection acquires a new sting. It is no longer “this is who I am”, but “this is what I chose not to change.” That shift, from identity to perceived negligence, is corrosive.
It also risks normalising a cycle of pre-marital optimisation. Today, it is weight. Tomorrow, it could be other metabolic tweaks. The body becomes a project to be completed before entering the market. Marriage, instead of being a social institution that accommodates human variance, becomes a filter that rewards those who can most effectively engineer themselves.
None of this is to argue against the legitimate medical use of these drugs. For many, they are life-changing in the best sense – improving health outcomes, reducing risk, enhancing quality of life. The problem is not the molecule. It is the market it enters.
India’s arranged marriage system has a remarkable ability to absorb new technologies and repurpose them for old hierarchies. WhatsApp biodatas, Instagram stalking, salary screenshots – each innovation has made the process more efficient, more inhumane. Ozempic will likely follow the same trajectory.
What makes this moment eerily familiar is not just the product, but the pattern. The Fair & Lovely creams did not create colourism. It monetised it. It told a generation that fairness was achievable, purchasable, and therefore expected. Ozempic does not create fat-shaming. It risks monetising it in a far more effective way. The fairness cream sat on a dressing table. This sits in a syringe. And that makes all the difference. Because when aspiration moves from cosmetics to chemistry, the stakes rise. The body is no longer just presented but it has potential to be altered. In a system as unforgiving as India’s arranged marriage market, alteration quickly becomes an obligation.
The tragedy is not that people will choose to change. It is that they may feel they have no choice at all.